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Abstract
Aim: To evaluate treatment data from DISCOVER (NCT02322762 and NCT02226822),
a global, prospective, observational study programme of patients with type 2 diabetes
initiating a second-line glucose-lowering therapy.
Materials and Methods: Data were collected using a standardized case report form.
First- and second-line treatments were assessed in 14 668 patients from 37 countries
across six regions. Among patients prescribed first-line metformin monotherapy, Firth
logistic regression models were used to assess factors associated with second-line
treatment choices.
Received: 13 March 2019 Revised: 28 June 2019 Accepted: 4 July 2019
DOI: 10.1111/dom.13830
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Diabetes Obes Metab. 2019;1–12. wileyonlinelibrary.com/journal/dom 1
Results: The most common first-line therapies were metformin monotherapy (57.9%)
and combinations of metformin with a sulphonylurea (14.6%). The most common
second-line therapies were combinations of metformin with other agents (72.2%),
including dipeptidyl peptidase-4 (DPP-4) inhibitors (25.1%) or sulphonylureas (21.3%).
Among patients prescribed first-line metformin monotherapy, the most common
second-line therapies were combinations of metformin with a DPP-4 inhibitor [32.8%;
across-region range (ARR): 2.4%-51.3%] or a sulphonylurea (30.0%; ARR: 18.3%-
63.6%); only a few patients received combinations of metformin with sodium-glucose
co-transporter-2 inhibitors (6.7%; ARR: 0.0%-10.8%) or glucagon-like peptide-1 recep-
tor agonists (1.9%; ARR: 0.1%-4.5%). Both clinical and non-medical factors were asso-
ciated with choice of second-line therapy after metformin monotherapy.
Conclusions: Fewer patients than expected received metformin monotherapy at first
line, and the use of newer therapies at second line was uncommon in some regions of
the world. Patients' socioeconomic status was associated with treatment patterns,
suggesting that therapy choices are influenced by cost and access.
K E YWORD S
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1 | INTRODUCTION
Optimal glycaemic control, along with the management of co-
morbidities such as hypertension and hyperlipidaemia, and prevention
of long-term complications, remains the cornerstone of the manage-
ment of patients with type 2 diabetes. Current clinical guidelines rec-
ommend an HbA1c target of less than 7.0% (53 mmol/mol) for most
patients.1-5 To achieve this target, most guidelines recommend the
use of metformin in conjunction with diet and lifestyle modifications
as first-line therapy. When metformin monotherapy fails to control
glycaemic levels, a second glucose-lowering drug should be added to
metformin in a timely fashion (within 3-6 months of an HbA1c value
above target).1-5 The Japanese guidelines take a different approach
and recommend monotherapy (metformin or other) in conjunction
with medical nutrition therapy as first-line pharmacological treatment;
the choice of first-line glucose-lowering agent should be tailored to
the patient's characteristics and metformin is not recommended over
any other agent.6
Although guidelines suggest using a personalized approach to select
second-line therapy based on patient characteristics (e.g. duration of
diabetes, presence of co-morbidities, age and risk of hypoglycaemia),
only the consensus report by the American Diabetes Association and
the European Association for the Study of Diabetes provides a clear
treatment algorithm based on the presence of atherosclerotic cardio-
vascular disease or chronic kidney disease.5 The wide variety of
glucose-lowering drug classes available as possible second-line thera-
pies results in difficult treatment decisions for clinicians.
DISCOVER is a 3-year, global programme of observational
research conducted in 38 countries, assessing the treatment of
patients with type 2 diabetes in routine clinical practice.7 The primary
objective of the study is to describe global disease management pat-
terns and associated clinical outcomes in people with type 2 diabetes
initiating a second-line glucose-lowering therapy. In many of the
included countries, data are currently scarce or non-existent. Here, we
report patterns of treatment changes from first to second line at the
start of the study in the overall patient population, and assess factors
associated with choice of second-line therapy in the subset of patients
who were prescribed metformin monotherapy as first-line treatment.
2 | MATERIALS AND METHODS
The methods for the DISCOVER study programme have been
reported in detail elsewhere,7,8 and are briefly summarized below.
2.1 | Study design
The DISCOVER study programme comprises two similar, 3-year, non-
interventional, prospective studies conducted in parallel in 38 coun-
tries, and including a total of 15 992 patients; DISCOVER
(NCT02322762) in 37 countries and J-DISCOVER (NCT02226822) in
Japan. Countries are grouped into regions according to World Health
Organization (WHO) categories: Africa (Algeria and South Africa);
Americas (Argentina, Brazil, Canada, Colombia, Costa Rica, Mexico
and Panama); South-East Asia (India and Indonesia); Europe (Austria,
Czech Republic, Denmark, France, Italy, Netherlands, Norway, Poland,
Russia, Spain, Sweden and Turkey); Eastern Mediterranean (Bahrain,
Egypt, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, Tunisia and the
United Arab Emirates); and Western Pacific (Australia, China, Japan,
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Malaysia, South Korea and Taiwan). The study protocols were approved
by the relevant clinical research ethics committees in each country and
institutional review boards at each site, and complied with the Declara-
tion of Helsinki, the International Conference on Harmonization of
Good Clinical Practice, and the local regulations for clinical research.
2.2 | Site and investigator selection
For each participating country, the characteristics of physicians and
clinical centres involved in the management of people with type 2 dia-
betes were assessed before the start of the study by conducting liter-
ature searches and interviewing key local diabetes experts who acted
as national coordinating investigators.9 Information on the propor-
tions of different types of practices (primary care centres, specialized
diabetes centres and different types of hospitals) and physicians (pri-
mary care physicians, diabetologists/endocrinologists, cardiologists
and other specialist physicians) treating patients with type 2 diabetes
were collated. A list of sites that would match these characteristics as
closely as possible was established for each country, and these sites
were invited to participate. Among the invited sites, approximately
one-third were able to take part and subsequently recruited patients
into the study.
2.3 | Patient enrolment
Inclusion and exclusion criteria were kept to a minimum to reflect the
diversity of patients treated in routine clinical practice. Briefly,
patients older than 18 years of age who had type 2 diabetes and who
were initiating a second-line glucose-lowering therapy (add-on or
switch, including switching between two agents in the same class)
were eligible for inclusion if: they were not pregnant; they were not
undergoing dialysis; they did not have a history of renal transplant;
and their first-line therapy was not an injectable agent, a herbal rem-
edy alone or natural medicine alone. Full inclusion and exclusion
criteria can be found in Table S1. Of note, J-DISCOVER enrolled only
patients who were receiving oral monotherapy as first-line treatment,
whereas DISCOVER enrolled patients who were receiving any type of
oral therapy (one or more oral agents, or a fixed dose combination).
The study protocol stated that participating physicians should invite
consecutive eligible patients to enrol in the study. All participating
patients provided signed informed consent. DISCOVER recruited
patients from December 2014 to June 2016; J-DISCOVER recruited
patients from September 2014 to December 2015.
2.4 | Data collection
Data were collected using a standardized electronic case report form
and were transferred to a central database via a web-based data cap-
ture system. Some data were extracted from existing electronic health
records in Canada, Denmark, France, Norway and Sweden; in these
countries, an abbreviated case report form was used. All data not auto-
matically extracted from electronic medical records were manually
transferred from existing medical records (electronic or otherwise) to
the web-based data capture system by the participating physicians. To
ensure data quality, a risk-based monitoring model was implemented.
On-site visits were organized at each data collection time point, and
key variables entered into the web-based data capture system were
checked against the original medical records for a random sample of
10% of patients at each site. Variables collected at baseline included:
physician and site characteristics; patient socioeconomic demo-
graphics; physiological variables [including body mass index (BMI) and
blood pressure]; laboratory test results (including HbA1c, fasting plasma
glucose and cholesterol levels); change in glucose-lowering therapies
and reason(s) for change; co-morbidities including microvascular
(nephropathy, retinopathy or neuropathy) and macrovascular (coronary
heart disease, cerebrovascular disease, peripheral artery disease, heart
failure or implantable cardioverter defibrillator use) diseases; and co-
medications. In line with the observational nature of the study, clinical
variables, such as HbA1c levels, were measured and recorded in accor-
dance with routine clinical practice; data collection was not mandatory
for any of the clinical variables. Similarly, the presence and severity of
co-morbidities such as microvascular and macrovascular complications
were not adjudicated and relied on the judgement of the participating
physicians. Reasons for changing first-line therapy and reasons for
choosing second-line therapy were entered in the data capture system
by the participating physicians, who selected one or several reasons
from predefined lists.
2.5 | Statistical analysis
For the present analysis, patients from China (n = 1293) were
excluded because complete data were not available at the time of
publication. Patients were also excluded if they had treatment infor-
mation missing in the database (n = 4), or if they had metformin mon-
otherapy recorded as both first- and second-line therapy (n = 27). The
total number of patients included in the analysis was therefore 14 668
(91.7% of the total DISCOVER population). Descriptive data are pres-
ented as numbers and percentages for categorical variables; mean
(standard deviation) values are reported for continuous variables.
Factors associated with choice of second-line therapy were exclu-
sively assessed in participants who were receiving metformin mon-
otherapy at first line, to increase homogeneity and eliminate
differences in choice of second-line therapy because of differences in
first-line therapy. Conventional logistic regression was deemed inap-
propriate to assess these associations because some second-line ther-
apies were prescribed to small numbers of patients. In such cases, the
maximum likelihood estimates used in the logistic regression model
may be biased. Firth logistic regression models were used instead
because they are based on penalized likelihood, which corrects the
small-sample bias.10,11 Based on the five most prescribed second-line
dual therapies after first-line metformin monotherapy, four models
were run testing: (a) likelihood of prescribing a dipeptidyl peptidase-4
(DPP-4) inhibitor relative to a sulphonylurea (SU), in combination with
metformin, (b) likelihood of prescribing a sodium-glucose co-trans-
porter-2 (SGLT-2) inhibitor relative to an SU, in combination with met-
formin, (c) likelihood of prescribing insulin relative to an SU, in
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TABLE 1 Patient baseline characteristics, overall and by region
Total Africa Americas South-East Asia Europe
Eastern
Mediterranean Western Pacific
(N = 14 668) (n = 811) (n = 2002) (n = 3351) (n = 3470) (n = 2179) (n = 2855)
Proportion of patients, % 100.0 5.5 13.6 22.8 23.7 14.9 19.5
Sex, male 7909 (53.9) 305 (37.6) 963 (48.1) 1846 (55.1) 1853 (53.5) 1278 (58.7) 1664 (58.3)
Missing 4 0 0 0 4 0 0
Age, years, mean (SD) 57.5 (12.0) 54.9 (11.2) 58.3 (11.8) 53.1 (11.3) 61.9 (10.9) 53.8 (10.8) 60.1 (12.7)
Missing 0 0 0 0 0 0 0
Self-reported ethnicity
Caucasian 3911 (27.9) 105 (13.0) 480 (29.4) 1 (0.0) 3014 (94.8) 165 (7.6) 146 (5.1)
Black 310 (2.2) 235 (29.0) 61 (3.7) 0 (0.0) 13 (0.4) 0 (0.0) 1 (0.0)
Asian 6299 (45.0) 177 (21.9) 9 (0.6) 3330 (99.5) 20 (0.6) 72 (3.3) 2691 (94.3)
Hispanic 942 (6.7) 1 (0.1) 928 (56.8) 0 (0.0) 11 (0.3) 0 (0.0) 2 (0.1)
Arabic 2147 (15.3) 199 (24.6) 4 (0.2) 2 (0.1) 12 (0.4) 1930 (88.9) 0 (0.0)
Mixed 213 (1.5) 91 (11.2) 115 (7.0) 0 (0.0) 4 (0.1) 0 (0.0) 3 (0.1)
Other 174 (1.2) 2 (0.2) 36 (2.2) 15 (0.4) 104 (3.3) 5 (0.2) 12 (0.4)
Missing 672 1 369 3 292 7 0
Education
No formal education 405 (3.0) 57 (7.3) 50 (3.2) 26 (0.8) 78 (2.5) 158 (7.7) 36 (1.4)
Primary (1-6 years) 2059 (15.5) 182 (23.2) 442 (28.7) 342 (10.3) 586 (19.1) 360 (17.6) 147 (5.7)
Secondary (7-13 years) 6600 (49.5) 420 (53.6) 587 (38.1) 1427 (43.2) 1778 (58.0) 765 (37.5) 1623 (62.8)
Higher education (>13 years) 4258 (32.0) 125 (15.9) 463 (30.0) 1510 (45.7) 623 (20.3) 758 (37.1) 779 (30.1)
Missing 1346 27 460 46 405 138 270
Main working status
Employed 5046 (36.7) 262 (32.7) 473 (29.9) 875 (26.2) 1094 (34.1) 952 (45.5) 1408 (50.8)
Self-employed 1679 (12.2) 59 (7.4) 343 (21.7) 751 (22.5) 170 (5.3) 209 (10.0) 147 (5.3)
Disabled 82 (0.6) 6 (0.7) 6 (0.4) 0 (0.0) 59 (1.8) 2 (0.1) 9 (0.3)
Not working 4009 (29.1) 336 (41.9) 428 (27.1) 1385 (41.4) 505 (15.8) 683 (32.6) 672 (24.3)
Retired 2892 (21.0) 139 (17.3) 330 (20.9) 332 (9.9) 1378 (43.0) 247 (11.8) 466 (16.8)
Other 67 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 67 (2.4)
Missing 875 9 422 8 264 86 86
Health insurance coverage
Private 2021 (14.7) 165 (20.7) 517 (32.3) 592 (18.8) 130 (3.9) 466 (22.3) 151 (5.4)
Public/government 8249 (59.8) 465 (58.2) 783 (48.8) 371 (11.8) 3038 (91.3) 1226 (58.7) 2366 (84.0)
Mixed 354 (2.6) 16 (2.0) 137 (8.5) 51 (1.6) 26 (0.8) 69 (3.3) 55 (2.0)
No insurance 3163 (22.9) 153 (19.1) 166 (10.4) 2140 (67.9) 134 (4.0) 327 (15.7) 243 (8.6)
Missing 881 12 399 197 142 91 40
Years since type 2 diabetes diagnosis, mean
(SD)
5.7 (5.3) 6.9 (5.7) 6.2 (6.1) 4.6 (4.1) 6.6 (5.4) 5.8 (5.1) 5.4 (5.6)
Missing 394 0 63 1 151 3 176
HbA1c, %, mean (SD) 8.3 (1.7) 8.6 (1.9) 8.5 (1.9) 8.6 (1.7) 8.1 (1.6) 8.7 (1.6) 7.9 (1.6)
Missing 2799 345 471 1307 470 135 71
BMI, kg/m2, mean (SD) 29.4 (6.0) 30.6 (6.2) 30.6 (6.1) 27.3 (4.5) 31.9 (6.1) 31.1 (5.7) 26.5 (5.4)
Missing 1150 13 202 207 258 324 146
Microvascular complicationsa 2843 (19.4) 118 (14.5) 302 (15.1) 556 (16.6) 808 (23.4) 398 (18.3) 661 (23.2)
Missing 18 0 0 0 18 0 0
(Continues)
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combination with metformin, and (d) likelihood of prescribing a
glucagon-like peptide-1 (GLP-1) receptor agonist relative to an SU, in
combination with metformin. Combinations of metformin and an SU
were chosen as the comparator because SUs are well established and
readily available in most countries, including the lower-income coun-
tries that participate in DISCOVER.
Multiple imputation was used to account for unreported data in
the Firth logistic regression models. At least one covariate was
missing for 34.5% of patients, with HbA1c having the highest pro-
portion of patients with missing data (18.2%); numbers of patients
with missing data are shown in Table S2. The imputation model
included all independent variables from the regression models [sex,
age, BMI, education duration, time since diabetes diagnosis, HbA1c
level, health insurance coverage status, employment status, medical
history (microvascular and macrovascular complications, chronic kid-
ney disease, minor and major hypoglycaemic events), physician's
specialty and region] as well as other variables that may be infor-
mative for the imputation of the variables included in the regres-
sion model [country, ethnicity, smoking status, systolic blood
pressure, total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol and triglyceride levels, and use of
co-medications (diuretics, angiotensin-converting enzyme inhibitor
or angiotensin II receptor blockers, beta blockers, statins and
acetylsalicylic acid)]. Iterative sequential regression was used to
sample missing values from the predictive distribution of each vari-
able conditional on all other variables. Ten randomly imputed
datasets were generated in this way; analyses were replicated on
each imputed dataset and the model estimates were pooled across
imputations. IVEware (Imputation and Variance Estimation Software;
University of Michigan's Survey Research Center, Institute for
Social Research, Ann Arbor, Michigan) was used to conduct the
imputation. SAS Proc MIANALYZE (SAS Institute Inc., Cary, North
Carolina) was used to pool the results. All other statistical analyses
were carried out using the SAS statistical software system (SAS
Institute Inc.).
3 | RESULTS
3.1 | Baseline patient characteristics
Table 1 shows the characteristics of the 14 668 patients included in
the present analysis. Overall, 53.9% of patients were male [across
region range (ARR): 37.6%-58.7%], the mean age was 57.5 years
(ARR: 53.1-61.9 years), and patients were mostly Asian (45.0%; ARR:
0.6%-99.5%) or Caucasian (27.9%; ARR: 0.0%-94.8%).
The mean HbA1c was 8.3% (ARR: 8.1%-8.7%) and the mean BMI
was 29.4 kg/m2 (ARR: 26.5-31.9 kg/m2). The majority of patients
(81.5%; ARR: 68.1%-92.9%) had secondary or higher education, and
48.9% (ARR: 39.4%-56.2%) were employed or self-employed. The mean
time from diagnosis of type 2 diabetes to initiation of second-line ther-
apy was 5.7 years (ARR: 4.6-6.9 years). A total of 19.4% (ARR: 14.5%-
23.4%) and 14.7% (ARR: 4.2%-30.5%) of patients had established
microvascular and macrovascular complications, respectively.
3.2 | Treatment patterns
Patients' first-line therapies and changes to second-line therapy for
the overall population are presented in Table 2; first- and second-line
therapies by region have been presented elsewhere.12 Metformin
monotherapy was the most commonly prescribed first-line treatment
[n = 8488 (57.9%)], followed by combinations of metformin and an SU
[n = 2139 (14.6%)], DPP-4 inhibitor monotherapies [n = 1172 (8.0%)]
and SU monotherapies [n = 1061 (7.2%)]. Overall, 11 837 participants
(80.7%) received metformin either alone or in combination at first line.
Combinations of metformin with either a DPP-4 inhibitor
[n = 3678 (25.1%)] or an SU [n = 3117 (21.3%)] were the most com-
monly prescribed second-line therapies. Only 634 patients (4.3%)
received an SGLT-2 inhibitor in combination with metformin at sec-
ond line; 10 patients (0.1%) received this combination at first line.
A small number of patients [n = 187 (1.3%)] received a GLP-1 receptor
agonist in combination with metformin at second line. Overall,
TABLE 1 (Continued)
Total Africa Americas South-East Asia Europe
Eastern
Mediterranean Western Pacific
(N = 14 668) (n = 811) (n = 2002) (n = 3351) (n = 3470) (n = 2179) (n = 2855)
Macrovascular complicationsb 2147 (14.7) 78 (9.6) 276 (13.8) 140 (4.2) 1045 (30.5) 236 (10.8) 372 (13.0)
Missing 42 0 0 0 42 0 0
History of major hypoglycaemiac 133 (1.0) 11 (1.4) 26 (1.6) 15 (0.5) 44 (1.3) 22 (1.1) 15 (0.5)
Missing 951 34 415 102 130 225 45
History of minor hypoglycaemiad 479 (3.5) 43 (5.5) 41 (2.6) 83 (2.6) 116 (3.5) 147 (7.4) 49 (1.7)
Missing 903 26 410 104 119 205 39
Data are n (%) unless otherwise indicated. Percentages were calculated for all patients with data available; patients with missing data were excluded.
Abbreviations: BMI, body mass index; SD, standard deviation.
aComposite of nephropathy, retinopathy and neuropathy.
bComposite of coronary heart disease, cerebrovascular disease, peripheral artery disease, heart failure and implantable cardioverter defibrillator use.
cHypoglycaemic events requiring external/third party assistance in the previous year.
dHypoglycaemic events that were self-reported, and which occurred in the previous 4 weeks.
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914 participants (6.2%) were prescribed insulin at second line, either
alone or in combination with other therapies.
Of the 11 195 participants who were receiving a monotherapy as
first-line treatment, 1378 (12.3%) switched to another monotherapy
(including changes within a drug class) as second-line treatment.
Among patients who were receiving metformin either as monotherapy
or as part of a combination therapy at first line (n = 11 016; after
excluding patients receiving insulin on its own or as part of a combina-
tion at second line), a total of 1634 (14.8%) were not prescribed met-
formin at second line.
Among participants who were prescribed metformin monotherapy
at first line (n = 8488), the most common second-line therapies were
combinations of metformin with either a DPP-4 inhibitor [n = 2780
(32.8%)] or an SU [n = 2549 (30.0%)]. Among patients prescribed SU
monotherapy at first line (n = 1061), the most common second-line
therapy was a combination of an SU with metformin [n = 349
(32.9%)], whereas among patients prescribed a DPP-4 inhibitor mon-
otherapy at first line (n = 1172), the most common second-line ther-
apy was a combination of a DPP-4 inhibitor with metformin
[n = 462 (39.4%)].
Among participants prescribed a combination of metformin with
either an SU (n = 2139) or a DPP-4 inhibitor (n = 489) at first line, the
most common second-line therapy was triple therapy combining met-
formin with both an SU and a DPP-4 inhibitor [n = 588 (27.5%) and
n = 131 (26.8%), respectively]. For a minority of patients [n = 252
(1.7%)], drug classes were recorded as being the same at both first
and second line; for these patients the change in treatment consisted
of a switch between agents in the same drug class.
3.3 | Factors associated with second-line treatment
choices in patients prescribed metformin
monotherapy as first-line treatment
The baseline characteristics of the subset of participants who received
metformin monotherapy at first line (n = 8488), and in which the fac-
tors associated with second-line treatment choices were assessed, are
shown in Table S2. Of note, mean HbA1c level was considerably
higher in patients prescribed insulin in combination with metformin at
second line than in other groups of patients (10.2% vs. 7.9%-8.5%;
Table S2). Lack of efficacy was the most commonly stated reason for
changing therapy in all treatment groups (72.8%-93.7%), but adverse
effects were more commonly reported as the reason for changing
treatment in the group of patients who discontinued metformin at
second line (n = 1194) than among other patient groups (20.0%
vs. 2.2%-3.9%; Table S3). Overall, expected efficacy was the most
commonly stated reason for choosing second-line therapies (63.2%),
and weight was often stated as a reason for choosing combinations of
metformin with an SGLT-2 inhibitor or a GLP-1 receptor agonist
(59.9% and 85.2%, respectively; Table S3).
TABLE 2 Choice of second-line glucose-lowering therapy, overall and according to first-line therapy
Second-line therapy
First-line therapy
Overall MET mono. SU mono.
DPP-
4i mono. Other mono. MET + SUa
MET +
DPP-4ia
MET + SU
+ DPP-4ib
MET +
other(s)
Other
comb.
N = 14 668 n = 8488 n = 1061 n = 1172 n = 474 n = 2139 n = 489 n = 217 n = 504 n = 124
MET monotherapy 238 (1.6) – 129 (12.2) 41 (3.5) 30 (6.3) 22 (1.0) 9 (1.8) 2 (0.9) 2 (0.4) 3 (2.4)
SU monotherapy 406 (2.8) 322 (3.8) 19 (1.8) 18 (1.5) 5 (1.1) 13 (0.6) 22 (4.5) 1 (0.5) 3 (0.6) 3 (2.4)
DPP-4i monotherapy 635 (4.3) 376 (4.4) 58 (5.5) 9 (0.8) 85 (17.9) 93 (4.3) 6 (1.2) 0 (0.0) 7 (1.4) 1 (0.8)
Other monotherapyc 534 (3.6) 224 (2.6) 14 (1.3) 37 (3.2) 11 (2.3) 183 (8.6) 20 (4.1) 14 (6.5) 27 (5.4) 4 (3.2)
MET + SUa 3117 (21.3) 2549 (30.0) 349 (32.9) 2 (0.2) 7 (1.5) 137 (6.4) 23 (4.7) 2 (0.9) 31 (6.2) 17 (13.7)
MET + DPP-4ia 3678 (25.1) 2780 (32.8) 61 (5.7) 462 (39.4) 11 (2.3) 243 (11.4) 58 (11.9) 3 (1.4) 56 (11.1) 4 (3.2)
MET + SGLT-2ia 634 (4.3) 571 (6.7) 2 (0.2) 0 (0.0) 25 (5.3) 15 (0.7) 15 (3.1) 2 (0.9) 3 (0.6) 1 (0.8)
MET + GLP-1 RAa 187 (1.3) 159 (1.9) 0 (0.0) 1 (0.1) 1 (0.2) 13 (0.6) 5 (1.0) 2 (0.9) 5 (1.0) 1 (0.8)
MET + SU + DPP-4ib 1040 (7.1) 135 (1.6) 88 (8.3) 10 (0.9) 0 (0.0) 588 (27.5) 131 (26.8) 29 (13.4) 37 (7.3) 22 (17.7)
MET + other(s)d 1936 (13.2) 812 (9.6) 67 (6.3) 13 (1.1) 70 (14.8) 507 (23.7) 132 (27.0) 85 (39.2) 219 (43.5) 31 (25.0)
Insuline 914 (6.2) 349 (4.1) 50 (4.7) 15 (1.3) 10 (2.1) 266 (12.4) 46 (9.4) 68 (31.3) 92 (18.3) 18 (14.5)
Other combinations 1349 (9.2) 211 (2.5) 224 (21.1) 564 (48.1) 219 (46.2) 59 (2.8) 22 (4.5) 9 (4.1) 22 (4.4) 19 (15.3)
Data are presented as n (%).
Abbreviations: comb., combination; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MET, metformin; mono.,
monotherapy; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; SU, sulphonylurea.
aDual therapy.
bTriple therapy.
cExcluding insulin monotherapy.
dExcluding combinations containing insulin.
eAlone or in combination with other agents.
6 NICOLUCCI ET AL.
Variations in the choice of second-line therapy according to region
are shown in Table S4. The most common second-line therapies over-
all were DPP-4 inhibitors (32.8%) or SUs (30.0%) in combination with
metformin; SUs in combination with metformin were the most com-
mon choice in Africa (63.6%), the Americas (34.2%) and South-East
Asia (41.2%), whereas a DPP-4 inhibitor in combination with metfor-
min was the most common choice in Europe (34.9%), the Eastern
Mediterranean region (51.3%) and the Western Pacific region (41.3%).
Expected efficacy was the most commonly stated reason for choosing
second-line therapies in all regions (43.4%-88.6%; Table S5). In Africa,
access, convenience and cost were also commonly selected reasons
for choosing a second-line therapy (17.4%, 14.0% and 11.8%, respec-
tively), whereas tolerability, weight and hypoglycaemia were common
factors in Europe (28.9%, 28.9% and 26.9%, respectively).
The results of the Firth logistic regression models assessing the fac-
tors associated with second-line treatment choices are shown in
Figure 1 for: (A) the likelihood of prescribing a DPP-4 inhibitor relative to
an SU, in combination with metformin; (B) the likelihood of prescribing
an SGLT-2 inhibitor relative to an SU, in combination with metformin;
(C) the likelihood of prescribing insulin relative to an SU, in combination
with metformin; and (D) the likelihood of prescribing a GLP-1 receptor
agonist relative to an SU, in combination with metformin.
3.3.1 | Likelihood of prescribing a DPP-4 inhibitor
relative to an SU, in combination with metformin
Patients were more likely to receive a combination of a DPP-4 inhibi-
tor with metformin than a combination of an SU with metformin if:
Male (vs. female)
Age (vs. <65 years)
 65 to <75 years
 ≥75 years
BMI (per 5 kg/m2 increment)
Education duration (vs. >13 years)
 No formal education
 Primary education (1–6 years)
 Secondary education (7–13 years)
Time since diabetes diagnosis (per 6-month increment)
HbA1c (vs. HbA1c <7.0%)
 7.0% to <8.0%
 8.0% to <9.0%
 ≥9.0%
Health insurance coverage (no vs. yes)
Employed or self employed (vs. unemployed)
Medical history (yes vs. no)
 Microvascular complicationsa
 Macrovascular complicationsb
 Chronic kidney disease
 Minor hypoglycaemic eventc
 Major hypoglycaemic eventd
Physician’s specialty (vs. PCP)
 Diabetology/endocrinology
 Internal medicine
 Other
Region (vs. Europe)
 Africa
 Americas
 South-East Asia
 Eastern Mediterranean
 Western Pacific
OR (95% CI)
(C)
1.20 (0.95–1.52)
1.42 (1.03–1.95)
1.26 (0.70–2.27)
1.42 (1.29–1.57)
0.17 (0.05–0.61)
0.38 (0.26–0.56)
0.63 (0.48–0.82)
1.00 (0.98–1.01)
1.17 (0.83–1.64)
0.72 (0.50–1.04)
0.68 (0.47–1.00)
0.61 (0.42–0.88)
1.51 (1.14–1.99)
1.21 (0.88–1.65)
0.65 (0.47–0.91)
0.28 (0.14–0.57)
0.32 (0.10–1.04)
2.89 (0.46–18.12)
6.00 (4.32–8.35)
1.19 (0.73–1.93)
13.16 (5.98–28.97)
 –e
0.29 (0.21–0.40)
0.09 (0.05–0.14)
0.07 (0.03–0.12)
0.66 (0.47–0.95)
(A)
OR (95% CI)
1.11 (0.97–1.29)
1.31 (1.10–1.57)
1.35 (1.00–1.81)
1.00 (0.94–1.07)
0.60 (0.38–0.94)
0.48 (0.39–0.59)
0.70 (0.60–0.82)
1.00 (0.99–1.01)
0.99 (0.79–1.23)
0.68 (0.54–0.85)
0.51 (0.40–0.65)
0.55 (0.46–0.67)
1.08 (0.92–1.27)
0.85 (0.70–1.02)
1.00 (0.83–1.20)
0.80 (0.55–1.16)
0.58 (0.35–0.94)
2.39 (0.91–6.27)
3.77 (3.11–4.58)
2.35 (1.86–2.98)
7.80 (4.78–12.74)
0.03 (0.02–0.05)
0.26 (0.21–0.32)
0.22 (0.17–0.29)
0.98 (0.78–1.23)
0.80 (0.64–0.99)
OR (95% CI)
(D)
1.05 (0.78–1.41)
0.98 (0.67–1.43)
0.58 (0.28–1.22)
0.99 (0.88–1.12)
0.88 (0.40–1.92)
0.96 (0.62–1.48)
0.94 (0.65–1.36)
1.02 (1.01–1.03)
0.67 (0.37–1.20)
1.15 (0.64–2.05)
3.52 (2.08–5.96)
0.82 (0.51–1.32)
0.97 (0.70–1.35)
0.87 (0.59–1.28)
0.94 (0.64–1.38)
1.07 (0.48–2.37)
1.34 (0.65–2.76)
3.72 (1.19–11.63)
1.51 (1.02–2.23)
0.69 (0.42–1.13)
0.33 (0.06–1.75)
0.30 (0.18–0.47)
0.30 (0.02–0.45)
0.09 (0.05–0.18)
0.38 (0.23–0.62)
0.10 (0.04–0.20)
OR (95% CI)
0.95 (0.63–1.45)
1.24 (0.70–2.20)
1.76 (0.65–4.74)
2.14 (1.82–2.51)
0.35 (0.09–1.40)
0.32 (0.17–0.62)
0.33 (0.20–0.55)
1.00 (0.98–1.02)
0.71 (0.38–1.33)
0.70 (0.38–1.31)
0.74 (0.39–1.39)
1.38 (0.64–2.98)
1.74 (1.07–2.81)
0.63 (0.33–1.21)
0.44 (0.24–0.79)
0.36 (0.09–1.14)
0.39 (0.09–1.77)
5.12 (0.47–56.01)
5.97 (3.47–10.27)
1.73 (0.88–3.41)
12.52 (3.10–50.55)
0.08 (0.03–0.20)
0.09 (0.05–0.16)
0.01 (0.00–0.03)
0.07 (0.03–0.16)
0.02 (0.00–0.08)
MET + SU
more likely
MET + DPP-4i
more likely
(B)
MET + SU
more likely
MET + SGLT-2i
more likely
MET + SU
more likely
MET + insulin
more likely
MET + SU
more likely
MET + GLP-1 RA
more likely
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F IGURE 1 Likelihood of receiving (A) MET and a DPP-4i, (B) MET and an SGLT-2i, (C) MET and insulin, and (D) MET and a GLP-1 RA,
compared with receiving MET and an SU in DISCOVER patients who received MET monotherapy as first-line treatment. Data are presented as
odds ratios (95% CI), estimated using Firth multinomial logistic regression models adjusted for all variables in the table.10 BMI, body mass index;
CI, confidence interval; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MET, metformin; OR, odds
ratio; PCP, primary care physician; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; SU, sulphonylurea. aComposite of nephropathy,
retinopathy and neuropathy. bComposite of coronary heart disease, cerebrovascular disease, peripheral artery disease, heart failure and
implantable cardioverter defibrillator use. cHypoglycaemic events requiring external/third-party assistance in the previous year. dHypoglycaemic
events that were self-reported and non-confirmed, and which occurred in the previous 4 weeks. eOdds ratio was not estimated because none of
the patients in Africa received an SGLT-2i
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they were older than 65 years of age (relative to <65 years of age);
they had a longer duration of education (>13 years relative to none,
1-6 years or 7-13 years); they had an HbA1c level less than 7.0% (rela-
tive to 8.0% to <9.0% and ≥ 9.0%); they had health insurance; they
had not experienced a minor hypoglycaemic event in the previous
4 weeks; and the second-line therapy was prescribed by a specialist
physician (relative to a primary care physician). Patients in Europe
were more likely than patients in Africa, the Americas, South-East Asia
or the Western Pacific region to be prescribed a DPP-4 inhibitor rela-
tive to an SU, in combination with metformin.
3.3.2 | Likelihood of prescribing an SGLT-2 inhibitor
relative to an SU, in combination with metformin
Factors significantly associated with having an increased likelihood of
receiving an SGLT-2 inhibitor relative to an SU in combination with
metformin included: being 65-74 years of age (relative to being
<65 years of age); increasing BMI (per 5 kg/m2 increment); being
employed or self-employed (relative to not being employed); having
health insurance coverage; and being prescribed a second-line therapy
by a diabetologist/endocrinologist (relative to a primary care physi-
cian). Conversely, factors significantly associated with having a lower
likelihood of receiving an SGLT-2 inhibitor relative to an SU in combi-
nation with metformin included: having less education (none,
1-6 years or 7-13 years, relative to >13 years); having an HbA1c level
of at least 9.0% (relative to <7.0%); and having a medical history of
macrovascular complications or chronic kidney disease (relative to
having no such medical history). In all regions, compared with Europe,
treatment with an SU in combination with metformin was more likely
than treatment with an SGLT-2 inhibitor in combination with metfor-
min (odds ratios could not be calculated for the likelihood of receiving
an SGLT-2 inhibitor relative to an SU in Africa because no patients in
this region received an SGLT-2 inhibitor) (Table S4).
3.3.3 | Likelihood of prescribing insulin relative to an
SU, in combination with metformin
Patients were more likely to be prescribed insulin than an SU in com-
bination with metformin if: they had a longer time since diagnosis of
diabetes (per 6-month increment); they had an HbA1c level of at least
9.0% (relative to <7.0%); they had experienced a major hypoglycaemic
event in the previous year; and the second-line therapy was pre-
scribed by a diabetologist or endocrinologist (relative to a primary care
physician). In all regions, compared with Europe, treatment with an SU
was more likely than treatment with insulin in combination with
metformin.
3.3.4 | Likelihood of prescribing a GLP-1 receptor
agonist relative to an SU, in combination with
metformin
Factors significantly associated with having an increased likelihood of
receiving a GLP-1 receptor agonist relative to an SU in combination
with metformin included: increasing BMI (per 5 kg/m2 increment);
being employed or self-employed (relative to not being employed);
and being prescribed a second-line therapy by a dia-
betologist/endocrinologist (relative to a primary care physician). Con-
versely, factors significantly associated with having a lower likelihood
of receiving a GLP-1 receptor agonist relative to an SU in combination
with metformin included: having less education (1-6 years or
7-13 years, relative to >13 years). In all regions, compared with
Europe, treatment with an SU in combination with metformin was
more likely than treatment with a GLP-1 receptor agonist in combina-
tion with metformin.
4 | DISCUSSION
This study provides important new global data on the treatment of
people with type 2 diabetes initiating a second-line glucose-lowering
therapy. Despite guideline recommendations that metformin mon-
otherapy should be used as first-line therapy in most patients,1-5
approximately a fifth of participants were not recorded as having
received metformin at first line, either alone or in combination with
another agent. SUs were widely used at both first and second line, as
were DPP-4 inhibitors, whereas, at second line, only 4.3% of patients
received an SGLT-2 inhibitor in combination with metformin, and only
1.3% received a GLP-1 receptor agonist in combination with metfor-
min. For patients who received metformin monotherapy at first line,
the most commonly prescribed second-line therapies were an SU or a
DPP-4 inhibitor in addition to metformin. Just under 15% of these
patients discontinued metformin at second line. These results are in
line with findings from a population-based, observational study con-
ducted in five European countries,13 which showed that metformin
monotherapy was the most commonly prescribed first-line treatment
(65%-88% of patients). In these patients, the most common second-
line therapies were combinations of metformin with either an SU or a
DPP-4 inhibitor.
The relatively high proportion of DISCOVER patients who
received first-line treatment with a combination therapy rather than
metformin monotherapy could reflect country-specific treatment
practices, or could be a result of late diagnosis of diabetes following
the recommendation to use combination therapies in patients with an
HbA1c level of at least 7.5% when the diagnosis of type 2 diabetes is
established.1 Among patients who were not prescribed metformin,
either alone or in combination at first line, explanations could include
contraindications, such as chronic kidney disease, or physician prefer-
ence for treatment with SUs or DPP-4 inhibitors. A survey conducted
in 2016 by the International Diabetes Federation and a recent epide-
miological study also suggest that the availability of metformin is sub-
optimal in some low- to medium-income countries.14,15 Of note, more
than 1 in 10 patients who received a monotherapy as first-line treat-
ment switched to another monotherapy when initiating second-line
treatment. This appears to be counter to clinical guidelines, which rec-
ommend the addition of a glucose-lowering agent when monotherapy
fails to control glycaemia.1-5 It should be noted, however, that some
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of these cases might reflect patients changing treatment because of
poor tolerability or affordability reasons rather than a lack of efficacy.
Among patients who received metformin monotherapy at first line
and who subsequently discontinued metformin at second line, the
reason stated for changing first-line therapy was lack of efficacy in
approximately 75%, and adverse effects in 20%. The use of SGLT-2
inhibitors and GLP-1 receptor agonists may become more common
given recent evidence from several cardiovascular outcomes trials and
a large international observational study that these classes of drugs
reduce cardiovascular event rates in patients at high cardiovascular
risk,16-21 and the recommendation in recent guidelines to use these
drugs in patients with established cardiovascular disease or chronic
kidney disease.5
In the multivariate analyses of factors associated with second-line
treatment choices among patients receiving metformin monotherapy
at first line, lower education increased the likelihood of SU prescrip-
tion relative to DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 recep-
tor agonists. This may reflect lower socioeconomic status and fewer
economic resources of these people, leading to the prescription of
more affordable drugs. These findings are in line with recent guide-
lines from WHO, which recommends the use of SUs as second-line
treatment in settings with limited health system resources.22 Further-
more, being employed or self-employed, relative to being disabled,
not working or retired, was also associated with an increased likeli-
hood of being prescribed an SGLT-2 inhibitor or a GLP-1 receptor
agonist relative to an SU; again, likely to be related to the cost of
treatment. Having an HbA1c level of at least 9.0% was a predictor of
SU prescription in addition to metformin, relative to DPP-4 or SGLT-2
inhibitors. This may reflect the high 6-month efficacy of SUs,23,24
leading to their use for rapid glycaemic control in patients with the
most severely elevated blood glucose levels. Our analysis also showed
a significant association between physician's specialty and second-line
therapy prescription after first-line metformin monotherapy. Endocri-
nologists and diabetologists were more likely to prescribe a DPP-4
inhibitor, an SGLT-2 inhibitor, insulin or a GLP-1 receptor agonist than
an SU, relative to primary care physicians. These findings suggest that
prescription preferences may differ in primary care physicians and
specialist physicians. Indeed, a recent survey in Japan highlighted that
specialists and non-specialists considered different factors when
selecting first-line therapy,25 which may also apply to second-line
treatment choices. However, such findings may not be generalizable
to other countries, and our results may reflect the fact that patients
with more severe disease, for whom these drugs would be
recommended,1,5 are more likely to be treated by specialists than pri-
mary care physicians. These results may also be confounded by the
fact that people with a lower socioeconomic status, who are more
likely to receive more affordable drugs such as SUs, may have limited
access to specialist care.26 In addition, having a history of either
macrovascular complications or chronic kidney disease was associated
with a decreased likelihood of receiving an SGLT-2 inhibitor relative
to an SU. Similarly, having a history of macrovascular complications
was associated with a decreased likelihood of receiving a GLP-1
receptor agonist relative to an SU, and having a history of minor
hypoglycaemic events was associated with a decreased likelihood of
receiving a DPP-4 inhibitor relative to an SU. Again, these findings
contradict the recommendations from recent clinical guidelines for
individualized treatment based on patients' characteristics,1-5
suggesting that non-medical reasons may play a significant part in
treatment choices.
An increased likelihood of receiving an insulin prescription relative
to SUs was strongly associated with very high HbA1c levels (≥9.0%)
and prescription by specialists (vs. primary care physicians). This is in
line with the recommendations to initiate insulin in patients with very
high HbA1c levels, and with the fact that these patients are more likely
to be managed in secondary rather than primary care.
In the regional component of the multivariate analyses, regions
were compared with Europe. With only one exception (DPP-4 inhibi-
tor prescription in the Eastern Mediterranean region), prescription of
SUs was more likely in every region than prescription of DPP-4 inhibi-
tors, SGLT-2 inhibitors or insulin. This is likely to reflect the relatively
high cost and low availability of these agents in some low- and
medium-income countries compared with SUs.14,15 In Africa, prescrip-
tion of SUs was much more likely than prescription of DPP-4 inhibi-
tors (compared with Europe), again reflecting the relative costs of the
two treatments. No patients in Africa received an SGLT-2 inhibitor.
These regional results are reflected in the descriptive assessment of
treatment options shown in Table S4; the proportion of patients
receiving an SU in combination with metformin was lower in Europe
(18.3%) than in any other region, whereas the rate of DPP-4 inhibitor
prescription with metformin was highest in the Eastern Mediterranean
region (51.3%).
Together, these results suggest that many patients in large parts
of the world are prescribed SUs rather than newer agents, such as
DPP-4 inhibitors, SGLT-2 inhibitors or GLP-1 receptor agonists, when
initiating second-line therapy, for economic and other non-medical
reasons. This a real concern because these newer drugs likely to have
a better cardiovascular safety profile than SUs.27 Indeed, the use of
SUs as second-line treatment (alone or in combination with metformin
after first-line metformin monotherapy relative to continuing metfor-
min monotherapy) has been shown to be associated with an increased
risk of myocardial infarction and all-cause mortality.28 Conversely, car-
diovascular outcomes trials have shown that the use of SGLT-2 inhibi-
tors and GLP-1 receptor agonists was associated with improved
cardiovascular outcomes relative to placebo, particularly in patients at
high cardiovascular risk.18 Similarly, a large observational study identi-
fied a decreased likelihood of cardiovascular events in patients using
SGLT-2 inhibitors compared with other glucose-lowering drugs.29
4.1 | Strengths and limitations
DISCOVER is a large and global study, which provides valuable and
unique insights into treatment patterns in patients with type 2 diabe-
tes globally, and also reflects variation in local practice because of dif-
ferences in healthcare systems, physicians' demographics and training,
site organization and recommendations from local clinical guidelines
across included countries. However, only a limited number of
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countries could be included for practical reasons, and the focus was
placed on lower-middle and upper-middle income countries for which
no alternative data sources are currently available. The USA and
Western European countries, such as Germany and the UK, were not
included because established and comprehensive databases already
exist (for example, the Diabetes Collaborative Registry in the USA,
The Health Improvement Network and Clinical Practice Research
Datalink databases in the UK, and the Disease Analyzer database in
Germany)30-33 and have been used to assess treatment patterns in
patients with type 2 diabetes in these countries.13,34,35 The substan-
tial efforts made before the start of the study to survey the types and
locations of medical practices treating patients with type 2 diabetes
have resulted in a heterogeneous patient population from diverse clin-
ical settings. However, as for any observational study of this type, a
fully representative patient sample was not possible to achieve.9 Fac-
tors limiting the ability of the study to be completely representative of
the treatment of patients with type 2 diabetes in each country include
infrastructure and other practical constraints, which prevented the
participation of some sites in rural locations and some primary care
sites. Consequently, there is overrepresentation of urban locations
and secondary care centres in the study. The likely result of this is an
overestimate of the quality of care in some countries, because sites in
urban locations may serve a well-educated and well-employed patient
population. In addition, secondary care centres employing specialist
physicians may provide a better quality of care than primary care cen-
tres. Finally, the limited number of included countries in each study
region limits the generalizability of the findings to the whole region.
In conclusion, results from this study provide a global picture of
treatment patterns in people with type 2 diabetes at initiation of
second-line glucose-lowering therapy in countries and regions with
few or no previous data. The findings showed that most patients
received metformin as first-line therapy, in line with clinical guidelines,
either as monotherapy or in combination with another agent. SUs and
DPP-4 inhibitors were also commonly prescribed at both first and sec-
ond line, with SGLT-2 inhibitors and GLP-1 receptor agonists pre-
scribed to only a minority of patients. Second-line therapy choices
were diverse and varied among regions; the most common reason for
changing therapy was lack of efficacy of first-line treatment. Factors
associated with the choice of second-line therapy included patient
characteristics, such as BMI and HbA1c level at the time of treatment
change, and medical history. Non-medical factors, such as access,
affordability and availability, also appear to play an important role in
the choice of SUs versus newer agents, such as SGLT-2 and DPP-4
inhibitors.
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